New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:57 EDTRLYPRelypsa price target raised to $41 from $25 at Stifel
Stifel believes that recent data emphasizes the primary role of Relypsa's patiromer in treating patients following the initial abatement of hyperkalemia, and it expects doctors to be impressed by the data. Stifel now expects Relypsa to launch a partnership in Europe and collect 45% royalties there starting in FY17. It keeps a Buy rating on the shares.
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
08:09 EDTRLYPRelypsa appoints Stephen Harrison as Chief Scientific Officer
Subscribe for More Information
December 15, 2014
11:35 EDTRLYPRelypsa price target raised to $63 from $58 at Wedbush
Subscribe for More Information
08:58 EDTRLYPRelypsa initiated with a Buy at BofA/Merrill
Target $55.
08:07 EDTRLYPRelypsa announces FDA acceptance of NDA for Patiromer FOS
Relypsa announced that the FDA has accepted for filing the New Drug Application, or NDA, for Patiromer for Oral Suspension, or Patiromer FOS, for the treatment of hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood. Relypsa expects written notification of NDA acceptance along with the Prescription Drug User Fee Act, or PDUFA, date as well as a preliminary indication regarding the need for an Advisory Committee meeting, in the day-74 letter from the FDA in early January 2015. The NDA is supported by eight clinical trials, including a Phase 3 program that was conducted under a Special Protocol Assessment, a long-term treatment trial that evaluated the safety and efficacy of Patiromer FOS in patients for up to one year, and an onset-of-action study that evaluated the time to potassium lowering action.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use